
WHAT IS CLAIMED IS:

1. A compound of structural Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein

one of A and B is independently selected from the group consisting of:

(1) aryl, and

(2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^a, and

the other of A and B is independently selected from the group consisting of:

(1) C_{3-12}cycloalkyl,

(2) C_{2-11}cycloheteroalkyl,

(3) -C_{1-6}alkyl-C_{3-12}cycloalkyl,

(4) -C_{1-6}alkyl-C_{2-11}cycloheteroalkyl,

(5) -C_{1-6}alkyl-O-C_{3-12}cycloalkyl, and

(6) -C_{1-6}alkyl-O-C_{2-11}cycloheteroalkyl,

wherein alkyl, cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to six substituents selected from R^b;

R^1 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl,

(3) -C_{2-6}alkenyl,

(4) -C_{2-6}alkynyl,

(5) -C_{3-6}cycloalkyl,

(6) -C_{2-6}cycloheteroalkyl,

(7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(8) -$(CH_2)_t$C(O)Rj,

(9) -$(CH_2)_t$C(O)NRᵉRj,

(10) -$(CH_2)_n$NRᵉC(O)Rj,

(11) -$(CH_2)_n$NRᵉC(O)ORj,

(12) -$(CH_2)_n$NRᵉC(O)N$(R^e)_2$,

(13) -$(CH_2)_n$NRᵉC(O)NRᵉRj,

(14) -$(CH_2)_n$NRᵉS(O)$_m$Rj,

(15) -$(CH_2)_n$NRᵉS(O)mN$(R^e)_2$,

(16) -$(CH_2)_n$NRᵉS(O)mNRᵉRj, and

(17) -$(CH_2)_n$NRᵉRj,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from Rᶜ;

R^2 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl,

(4) -C_{2-6}alkenyl,

(5) -C_{2-6}alkynyl,

(6) -C_{3-6}cycloalkyl,

(7) -C_{2-6}cycloheteroalkyl,

(8) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(9) -$(CH_2)_s$C(O)Rj,

(10) -$(CH_2)_s$C(O)NRᵉRj,

(11) -$(CH_2)_s$NRᵉC(O)Rj,

(12) -$(CH_2)_s$NRᵉC(O)ORj,

(13) -$(CH_2)_s$$NR^eC(O)N(R^e)_2$,

(14) -$(CH_2)_s$$NR^eC(O)NR^eR^j$,

(15) -$(CH_2)_s$$NR^eS(O)_mR^j$,

(16) -$(CH_2)_s$$NR^eS(O)mN(R^e)_2$,

(17) -$(CH_2)_s$$NR^eS(O)mNR^eR^j$, and

(18) -$(CH_2)_s$$NR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^d,

wherein R^2 and R^3 and the carbon atoms they are connected to can from a -C_{3-5}cycloalkyl ring, and wherein R^2 and R^4 and the carbon atoms they are connected to can from a -C_{3-5}cycloalkyl ring;

R^3 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl,

(4) -C_{2-6}alkenyl,

(5) -C_{2-6}alkynyl,

(6) -C_{3-6}cycloalkyl,

(7) -C_{2-6}cycloheteroalkyl,

(8) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(9) -$(CH_2)_s$$C(O)R^j$,

(10) -$(CH_2)_s$$C(O)NR^eR^j$,

(11) -$(CH_2)_s$$NR^eC(O)R^j$,

(12) -$(CH_2)_s$$NR^eC(O)OR^j$,

(13) -$(CH_2)_s$$NR^eC(O)N(R^e)_2$,

(14) -$(CH_2)_s$$NR^eC(O)NR^eR^j$,

(15) -$(CH_2)_s$$NR^eS(O)_mR^j$,

(16) -$(CH_2)_s$$NR^eS(O)mN(R^e)_2$,

(17) $-(CH_2)_sNR^eS(O)mNR^eR^j$, and

(18) $-(CH_2)_sNR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^4 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) $-C_{1-6}$alkyl,

(4) $-C_{2-6}$alkenyl,

(5) $-C_{2-6}$alkynyl,

(6) $-C_{3-6}$cycloalkyl,

(7) $-C_{2-6}$cycloheteroalkyl,

(8) $-C_{1-6}$alkyl-O-C_{1-6}alkyl-,

(9) $-(CH_2)_sC(O)R^j$,

(10) $-(CH_2)_sC(O)NR^eR^j$,

(11) $-(CH_2)_sNR^eC(O)R^j$,

(12) $-(CH_2)_sNR^eC(O)OR^j$,

(13) $-(CH_2)_sNR^eC(O)N(R^e)_2$,

(14) $-(CH_2)_sNR^eC(O)NR^eR^j$,

(15) $-(CH_2)_sNR^eS(O)_mR^j$,

(16) $-(CH_2)_sNR^eS(O)mN(R^e)_2$,

(17) $-(CH_2)_sNR^eS(O)mNR^eR^j$, and

(18) $-(CH_2)_sNR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^f, and

wherein R^4 and R^5 and the carbon atoms they are connected to can from a $-C_{3-5}$cycloalkyl ring;

R^5 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl,

(4) -C_{2-6}alkenyl,

(5) -C_{2-6}alkynyl,

(6) -C_{3-6}cycloalkyl,

(7) -C_{2-6}cycloheteroalkyl,

(8) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(9) -$(CH_2)_sC(O)R^j$,

(10) -$(CH_2)_sC(O)NR^eR^j$,

(11) -$(CH_2)_sNR^eC(O)R^j$,

(12) -$(CH_2)_sNR^eC(O)OR^j$,

(13) -$(CH_2)_sNR^eC(O)N(R^e)_2$,

(14) -$(CH_2)_sNR^eC(O)NR^eR^j$,

(15) -$(CH_2)_sNR^eS(O)_mR^j$,

(16) -$(CH_2)_sNR^eS(O)mN(R^e)_2$,

(17) -$(CH_2)_sNR^eS(O)mNR^eR^j$, and

(18) -$(CH_2)_sNR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^f, and

wherein R^5 and R^7 and the carbon atoms they are attached to may form a 4-, 5- or 6- membered saturated ring;

R^6 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl,

(4) -C_{2-6}alkenyl,

(5) -C_{2-6}alkynyl,

(6) -C_{3-6}cycloalkyl,

(7) -C_{2-6}cycloheteroalkyl,

(8) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(9) -$(CH_2)_sC(O)R^j$,

(10) -$(CH_2)_sC(O)NR^eR^j$,

(11) -$(CH_2)_sNR^eC(O)R^j$,

(12) -$(CH_2)_sNR^eC(O)OR^j$,

(13) -$(CH_2)_sNR^eC(O)N(R^e)_2$,

(14) -$(CH_2)_sNR^eC(O)NR^eR^j$,

(15) -$(CH_2)_sNR^eS(O)_mR^j$,

(16) -$(CH_2)_sNR^eS(O)mN(R^e)_2$,

(17) -$(CH_2)_sNR^eS(O)mNR^eR^j$, and

(18) -$(CH_2)_sNR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^g, and

wherein R^6 and R^7 and the carbon atoms they are connected to can from a -C_{3-5}cycloalkyl ring;

R^7 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl,

(4) -C_{2-6}alkenyl,

(5) -C_{2-6}alkynyl,

(6) -C_{3-6}cycloalkyl,

(7) -C_{2-6}cycloheteroalkyl,

(8) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(9) -$(CH_2)_sC(O)R^j$,

(10) -$(CH_2)_sC(O)NR^eR^j$,

(11) -$(CH_2)_sNR^eC(O)R^j$,

(12) -$(CH_2)_sNR^eC(O)OR^j$,

(13) -$(CH_2)_s$$NR^e$C(O)N$(R^e)_2$,

(14) -$(CH_2)_s$$NR^e$C(O)$NR^eR^j$,

(15) -$(CH_2)_s$$NR^eS(O)_m$$R^j$,

(16) -$(CH_2)_s$$NR^e$S(O)mN$(R^e)_2$,

(17) -$(CH_2)_s$$NR^e$S(O)m$NR^eR^j$, and

(18) -$(CH_2)_s$$NR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^g;

R^8 is selected from the group consisting of:

(1) hydrogen,

(2) -$C_{1\text{-}6}$alkyl,

(3) -$C_{3\text{-}6}$cycloalkyl, and

(4) -$C_{2\text{-}6}$cycloheteroalkyl,

wherein each alkyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from halogen;

R^9 is selected from the group consisting of:

(1) hydrogen,

(2) -$C_{1\text{-}6}$alkyl,

(3) -$C_{2\text{-}6}$alkenyl, and

(4) -$C_{2\text{-}6}$alkynyl,

wherein each alkyl, alkenyl and alkynyl is unsubstituted or substituted with one to five substituents selected from halogen;

each R^a is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) –$S(O)_2C_{1\text{-}6}$alkyl,

(5) -$C_{1\text{-}6}$alkyl,

(6) -C_{2-6}alkenyl,

(7) -C_{2-6}alkynyl,

(8) -C_{3-6}cycloalkyl,

(9) -C_{2-6}cycloheteroalkyl,

(10) aryl,

(11) heteroaryl,

(12) –C_{1-6}alkyl-aryl,

(13) –C_{1-6}alkyl-heteroaryl,

(14) –C_{1-6}alkyl-C_{3-6}cycloalkyl,

(15) –C_{1-6}alkyl-C_{2-6}cycloheteroalkyl,

(16) -C_{2-6}alkenyl-C_{3-6}cycloalkyl,

(17) -C_{2-6}alkenyl-C_{2-6}cycloheteroalkyl,

(18) –C_{2-6}alkenyl-aryl,

(19) -C_{2-6}alkenyl-heteroaryl,

(20) -C_{2-6}alkynyl-C_{3-6}cycloalkyl,

(21) -C_{2-6}alkynylC_{2-6}cycloheteroalkyl,

(22) -C_{2-6}alkynyl-aryl,

(23) -C_{2-6}alkynyl–heteroaryl,

(24) -OH,

(25) -$(CH_2)_p$-O-C_{1-6}alkyl,

(26) -$(CH_2)_p$ -O-C_{2-6}alkenyl,

(27) -$(CH_2)_p$ -O-C_{2-6}alkynyl,

(28) –$(CH_2)_p$ -O-C_{3-6}cycloalkyl,

(29) –$(CH_2)_p$ -O-C_{2-6}cycloheteroalkyl,

(30) –$(CH_2)_p$ -O-aryl,

(31) –$(CH_2)_p$ -O-heteroaryl,

(32) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

(33) -OC_{1-6}alkyl-C_{2-6}cycloheteroalkyl,

(34) -OC_{1-6}alkyl-aryl,

(35) -OC_{1-6}alkyl-heteroaryl,

(36) -$S(O)_rR^h$,

(37) -C_{1-6}alkyl-$S(O)_rR^h$,

(38) -$N(R^k)_2$,

(39) -$C(O)R^L$, and

(40) –NR^kR^L,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl;

each R^b is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) –$S(O)_2C_{1-6}$alkyl,

(5) -C_{1-6}alkyl,

(6) -C_{1-6}alkenyl,

(7) -C_{2-6}alkynyl,

(8) -C_{3-6}cycloalkyl,

(9) -C_{2-6}cycloheteroalkyl,

(10) aryl,

(11) heteroaryl,

(12) –C_{1-6}alkyl-aryl,

(13) –C_{1-6}alkyl-heteroaryl,

(14) –C_{1-6}alkyl-C_{3-6}cycloalkyl,

(15) –C_{1-6}alkyl-C_{2-6}cycloheteroalkyl,

(16) -C_{2-6}alkenyl-C_{3-6}cycloalkyl,

(17) -C_{2-6}alkenyl-C_{2-6}cycloheteroalkyl,

(18) –C_{2-6}alkenyl-aryl,

(19) -C_{2-6}alkenyl-heteroaryl,

(20) -C_{2-6}alkynyl-C_{3-6}cycloalkyl,

(21) -C_{2-6}alkynyl-C_{2-6}cycloheteroalkyl,

(22) -C_{2-6}alkynyl-aryl,

(23) -C_{2-6}alkynyl–heteroaryl,

(24) -OH,

(25) -$(CH_2)_q$-O-C_{1-6}alkyl,

(26) -$(CH_2)_q$-O-C_{2-6}alkenyl,

(27) -$(CH_2)_q$ -O-C_{2-6}alkynyl,

(28) –$(CH_2)_q$ -O-C_{3-6}cycloalkyl,

(29) –$(CH_2)_q$ -O-C_{2-6}cycloheteroalkyl,

(30) –$(CH_2)_q$ -O-aryl,

(31) –$(CH_2)_q$ -O-heteroaryl,

(32) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

(33) -OC_{1-6}alkyl-C_{2-6}cycloheteroalkyl,

(34) -OC_{1-6}alkyl-aryl,

(35) -OC_{1-6}alkyl-heteroaryl,

(36) -$S(O)_rR^i$,

(37) -C_{1-6}alkyl-$S(O)_rR^i$,

(38) -$N(R^k)_2$,

(39) -$C(O)R^L$, and

(40) –NR^kR^L,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;

R^c is selected from:

(1) -C_{1-6}alkyl,

(2) OH,

(3) halogen, and

(4) -OC_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three halogens;

R^d is selected from:

(1) -C_{1-6}alkyl,

(2) OH,

(3) halogen, and

(4) -OC_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three halogens;

R^e is selected from:

(1) hydrogen, and

(2) C_{1-6}alkyl;

R^f is selected from:

(1) -C_{1-6}alkyl,

(2) OH,

(3) halogen, and

(4) -OC_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three halogens;

R^g is selected from:

(1) -C_{1-6}alkyl,

(2) OH,

(3) halogen, and

(4) -OC_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three halogens;

R^h is selected from:

(1) hydrogen,

(2) C_{1-6}alkyl,

(3) C_{3-6}cycloalkyl,

(4) aryl, and

(5) heteroaryl;

R^i is selected from:

(1) hydrogen,

(2) C_{1-6}alkyl,

(3) C_{3-6}cycloalkyl,

(4) aryl, and

(5) heteroaryl;

R^j is selected from:

(1) hydrogen,

(2) C_{1-6}alkyl,

(3) C_{3-6}alkenyl,

(4) C_{3-6}alkynyl,

(5) C_{3-6}cycloalkyl,

(6) C_{2-5}cycloheteroalkyl,

(7) aryl, and

(8) heteroaryl;

R^k is selected from:

(1) hydrogen, and

(2) C_{1-6}alkyl;

R^L is selected from:

(1) hydrogen,

(2) C_{1-6}alkyl,

(3) C_{3-6}cycloalkyl,

(4) aryl, and

(5) heteroaryl;

m is independently selected from 0, 1 and 2;

n is independently selected from 2, 3, 4, 5 and 6;

p is independently selected from 0, 1, 2 and 3;


q is independently selected from 0, 1, 2 and 3;

r is independently selected from 0, 1 and 2;

s is independently selected from 0, 1, 2, 3, 4, 5, and 6; and

t is independently selected from 0, 1, 2, 3, 4, 5, and 6.

2. A compound of structural Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein

one of A and B is independently selected from the group consisting of:

(1) aryl, and

(2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^a, and

the other of A and B is independently selected from the group consisting of:

(1) -C_{3-12}cycloalkyl,

(2) -C_{2-11}cycloheteroalkyl,

(3) -C_{1-6}alkyl-C_{3-12}cycloalkyl,

(4) -C_{1-6}alkyl-C_{2-11}cycloheteroalkyl,

(5) -C_{1-6}alkyl-O-C_{3-12}cycloalkyl, and

(6) -C_{1-6}alkyl-O-C_{2-11}cycloheteroalkyl,

wherein alkyl, cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to six substituents selected from R^b;

R^1 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl,

(3) -C_{2-6}alkenyl,

(4) -C_{2-6}alkynyl,

(5) -C_{3-6}cycloalkyl,

(6) -C_{2-6}cycloheteroalkyl,

(7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(8) -$(CH_2)_tC(O)R^j$,

(9) -$(CH_2)_tC(O)NR^eR^j$,

(10) -$(CH_2)_nNR^eC(O)R^j$,

(11) -$(CH_2)_nNR^eC(O)OR^j$,

(12) -$(CH_2)_nNR^eC(O)N(R^e)_2$,

(13) -$(CH_2)_nNR^eC(O)NR^eR^j$,

(14) -$(CH_2)_nNR^eS(O)_mR^j$,

(15) -$(CH_2)_nNR^eS(O)mN(R^e)_2$,

(16) -$(CH_2)_nNR^eS(O)mNR^eR^j$, and

(17) -$(CH_2)_nNR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^c;

R^2 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl,

(3) -C_{2-6}alkenyl,

(4) -C_{2-6}alkynyl,

(5) -C_{3-6}cycloalkyl,

(6) -C_{2-6}cycloheteroalkyl,

(7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(8) -$(CH_2)_sC(O)R^j$,

(9) -$(CH_2)_sC(O)NR^eR^j$,

(10) -$(CH_2)_sNR^eC(O)R^j$,

(11) -$(CH_2)_s$$NR^eC(O)OR^j$,

(12) -$(CH_2)_s$$NR^eC(O)N(R^e)_2$,

(13) -$(CH_2)_s$$NR^eC(O)NR^eR^j$,

(14) -$(CH_2)_s$$NR^eS(O)_mR^j$,

(15) -$(CH_2)_s$$NR^eS(O)mN(R^e)_2$,

(16) -$(CH_2)_s$$NR^eS(O)mNR^eR^j$, and

(17) -$(CH_2)_s$$NR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^d,

wherein R^2 and R^3 and the carbon atoms they are connected to can from a -C_{3-5}cycloalkyl ring, and wherein R^2 and R^4 and the carbon atoms they are connected to can from a -C_{3-5}cycloalkyl ring;

R^3 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl,

(3) -C_{2-6}alkenyl,

(4) -C_{2-6}alkynyl,

(5) -C_{3-6}cycloalkyl,

(6) -C_{2-6}cycloheteroalkyl,

(7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(8) -$(CH_2)_s$$C(O)R^j$,

(9) -$(CH_2)_s$$C(O)NR^eR^j$,

(10) -$(CH_2)_s$$NR^eC(O)R^j$,

(11) -$(CH_2)_s$$NR^eC(O)OR^j$,

(12) -$(CH_2)_s$$NR^eC(O)N(R^e)_2$,

(13) -$(CH_2)_s$$NR^eC(O)NR^eR^j$,

(14) -$(CH_2)_s$$NR^eS(O)_mR^j$,

(15) -$(CH_2)_s$$NR^eS(O)mN(R^e)_2$,

(16) -$(CH_2)_s$$NR^eS(O)mNR^eR^j$, and

(17) -$(CH_2)_s$$NR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^4 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl,

(3) -C_{2-6}alkenyl,

(4) -C_{2-6}alkynyl,

(5) -C_{3-6}cycloalkyl,

(6) -C_{2-6}cycloheteroalkyl,

(7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(8) -$(CH_2)_s$$C(O)R^j$,

(9) -$(CH_2)_s$$C(O)NR^eR^j$,

(10) -$(CH_2)_s$$NR^eC(O)R^j$,

(11) -$(CH_2)_s$$NR^eC(O)OR^j$,

(12) -$(CH_2)_s$$NR^eC(O)N(R^e)_2$,

(13) -$(CH_2)_s$$NR^eC(O)NR^eR^j$,

(14) -$(CH_2)_s$$NR^eS(O)_mR^j$,

(15) -$(CH_2)_s$$NR^eS(O)mN(R^e)_2$,

(16) -$(CH_2)_s$$NR^eS(O)mNR^eR^j$, and

(17) -$(CH_2)_s$$NR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^f, and

wherein R^4 and R^5 and the carbon atoms they are connected to can from a -C_{3-5}cycloalkyl ring;

R^5 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl,

(3) -C_{2-6}alkenyl,

(4) -C_{2-6}alkynyl,

(5) -C_{3-6}cycloalkyl,

(6) -C_{2-6}cycloheteroalkyl,

(7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(8) -$(CH_2)_sC(O)R^j$,

(9) -$(CH_2)_sC(O)NR^eR^j$,

(10) -$(CH_2)_sNR^eC(O)R^j$,

(11) -$(CH_2)_sNR^eC(O)OR^j$,

(12) -$(CH_2)_sNR^eC(O)N(R^e)_2$,

(13) -$(CH_2)_sNR^eC(O)NR^eR^j$,

(14) -$(CH_2)_sNR^eS(O)_mR^j$,

(15) -$(CH_2)_sNR^eS(O)mN(R^e)_2$,

(16) -$(CH_2)_sNR^eS(O)mNR^eR^j$, and

(17) -$(CH_2)_sNR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^f, and

wherein R^5 and R^7 and the carbon atoms they are attached to may form a 4-, 5- or 6- membered saturated ring;

R^6 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl,

(3) -C_{2-6}alkenyl,

(4) -C_{2-6}alkynyl,

(5) -C_{3-6}cycloalkyl,

(6) -C_{2-6}cycloheteroalkyl,

(7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

(8) $-(CH_2)_sC(O)R^j$,

(9) $-(CH_2)_sC(O)NR^eR^j$,

(10) $-(CH_2)_sNR^eC(O)R^j$,

(11) $-(CH_2)_sNR^eC(O)OR^j$,

(12) $-(CH_2)_sNR^eC(O)N(R^e)_2$,

(13) $-(CH_2)_sNR^eC(O)NR^eR^j$,

(14) $-(CH_2)_sNR^eS(O)_mR^j$,

(15) $-(CH_2)_sNR^eS(O)mN(R^e)_2$,

(16) $-(CH_2)_sNR^eS(O)mNR^eR^j$, and

(17) $-(CH_2)_sNR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^g, and

wherein R^6 and R^7 and the carbon atoms they are connected to can from a $-C_{3-5}$cycloalkyl ring;

R^7 is selected from the group consisting of:

(1) hydrogen,

(2) $-C_{1-6}$alkyl,

(3) $-C_{2-6}$alkenyl,

(4) $-C_{2-6}$alkynyl,

(5) $-C_{3-6}$cycloalkyl,

(6) $-C_{2-6}$cycloheteroalkyl,

(7) $-C_{1-6}$alkyl-O-C_{1-6}alkyl-,

(8) $-(CH_2)_sC(O)R^j$,

(9) $-(CH_2)_sC(O)NR^eR^j$,

(10) $-(CH_2)_sNR^eC(O)R^j$,

(11) $-(CH_2)_sNR^eC(O)OR^j$,

(12) $-(CH_2)_sNR^eC(O)N(R^e)_2$,

(13) $-(CH_2)_sNR^eC(O)NR^eR^j$,

(14) $-(CH_2)_sNR^eS(O)_mR^j$,

(15) -$(CH_2)_s$$NR^eS(O)_mN(R^e)_2$,

(16) -$(CH_2)_s$$NR^eS(O)_mNR^eR^j$, and

(17) -$(CH_2)_s$$NR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^g;

R^8 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl,

(3) -C_{3-6}cycloalkyl, and

(4) -C_{2-6}cycloheteroalkyl,

wherein each alkyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from halogen;

R^9 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl,

(3) -C_{2-6}alkenyl, and

(4) -C_{2-6}alkynyl,

wherein each alkyl, alkenyl and alkynyl is unsubstituted or substituted with one to five substituents selected from halogen;

each R^a is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) –$S(O)_2C_{1-6}$alkyl,

(5) -C_{1-6}alkyl,

(6) -C_{2-6}alkenyl,

(7) -C_{2-6}alkynyl,

(8) -C_{3-6}cycloalkyl,

(9) -C_{2-6}cycloheteroalkyl,

(10) aryl,

(11) heteroaryl,

(12) –C_{1-6}alkyl-aryl,

(13) –C_{1-6}alkyl-heteroaryl,

(14) –C_{1-6}alkyl-C_{3-6}cycloalkyl,

(15) –C_{1-6}alkyl-C_{2-6}cycloheteroalkyl,

(16) -C_{2-6}alkenyl-C_{3-6}cycloalkyl,

(17) -C_{2-6}alkenyl-C_{2-6}cycloheteroalkyl,

(18) –C_{2-6}alkenyl-aryl,

(19) -C_{2-6}alkenyl-heteroaryl,

(20) -C_{2-6}alkynyl-C_{3-6}cycloalkyl,

(21) -C_{2-6}alkynylC_{2-6}cycloheteroalkyl,

(22) -C_{2-6}alkynyl-aryl,

(23) -C_{2-6}alkynyl–heteroaryl,

(24) -OH,

(25) -$(CH_2)_p$-O-C_{1-6}alkyl,

(26) -$(CH_2)_p$ -O-C_{2-6}alkenyl,

(27) -$(CH_2)_p$ -O-C_{2-6}alkynyl,

(28) –$(CH_2)_p$ -O-C_{3-6}cycloalkyl,

(29) –$(CH_2)_p$ -O-C_{2-6}cycloheteroalkyl,

(30) –$(CH_2)_p$ -O-aryl,

(31) –$(CH_2)_p$ -O-heteroaryl,

(32) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

(33) -OC_{1-6}alkyl-C_{2-6}cycloheteroalkyl,

(34) -OC_{1-6}alkyl-aryl,

(35) -OC_{1-6}alkyl-heteroaryl,

(36) -$S(O)_rR^h$,

(37) -C_{1-6}alkyl-$S(O)_rR^h$,

(38) -$N(R^k)_2$,

(39) -C(O)R^L, and

(40) –NR^kR^L,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, $C_{1\text{-}6}$alkyl, and -O$C_{1\text{-}6}$alkyl;

each R^b is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) –$S(O)_2C_{1\text{-}6}$alkyl,

(5) -$C_{1\text{-}6}$alkyl,

(6) -$C_{1\text{-}6}$alkenyl,

(7) -$C_{2\text{-}6}$alkynyl,

(8) -$C_{3\text{-}6}$cycloalkyl,

(9) -$C_{2\text{-}6}$cycloheteroalkyl,

(10) aryl,

(11) heteroaryl,

(12) –$C_{1\text{-}6}$alkyl-aryl,

(13) –$C_{1\text{-}6}$alkyl-heteroaryl,

(14) –$C_{1\text{-}6}$alkyl-$C_{3\text{-}6}$cycloalkyl,

(15) –$C_{1\text{-}6}$alkyl-$C_{2\text{-}6}$cycloheteroalkyl,

(16) -$C_{2\text{-}6}$alkenyl-$C_{3\text{-}6}$cycloalkyl,

(17) -$C_{2\text{-}6}$alkenyl-$C_{2\text{-}6}$cycloheteroalkyl,

(18) –$C_{2\text{-}6}$alkenyl-aryl,

(19) -$C_{2\text{-}6}$alkenyl-heteroaryl,

(20) -$C_{2\text{-}6}$alkynyl-$C_{3\text{-}6}$cycloalkyl,

(21) -$C_{2\text{-}6}$alkynyl-$C_{2\text{-}6}$cycloheteroalkyl,

(22) -$C_{2\text{-}6}$alkynyl-aryl,

(23) -$C_{2\text{-}6}$alkynyl–heteroaryl,

(24) -OH,

(25) -$(CH_2)_q$-O-$C_{1\text{-}6}$alkyl,

(26) -$(CH_2)_q$-O-C_{2-6}alkenyl,

(27) -$(CH_2)_q$ -O-C_{2-6}alkynyl,

(28) –$(CH_2)_q$ -O-C_{3-6}cycloalkyl,

(29) –$(CH_2)_q$ -O-C_{2-6}cycloheteroalkyl,

(30) –$(CH_2)_q$ -O-aryl,

(31) –$(CH_2)_q$ -O-heteroaryl,

(32) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

(33) -OC_{1-6}alkyl-C_{2-6}cycloheteroalkyl,

(34) -OC_{1-6}alkyl-aryl,

(35) -OC_{1-6}alkyl-heteroaryl,

(36) -$S(O)_rR^i$,

(37) -C_{1-6}alkyl-$S(O)_rR^i$,

(38) -$N(R^k)_2$,

(39) -$C(O)R^L$, and

(40) –NR^kR^L,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;

R^c is selected from:

(1) -C_{1-6}alkyl,

(2) OH,

(3) halogen, and

(4) -OC_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three halogens;

R^d is selected from:

(1) -C_{1-6}alkyl,

(2) OH,

(3) halogen, and

(4) -OC_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three halogens;

R^e is selected from:

(1) hydrogen, and

(2) C_{1-6}alkyl;

R^f is selected from:

(1) -C_{1-6}alkyl,

(2) OH,

(3) halogen, and

(4) -OC_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three halogens;

R^g is selected from:

(1) -C_{1-6}alkyl,

(2) OH,

(3) halogen, and

(4) -OC_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to three halogens;

R^h is selected from:

(1) hydrogen,

(2) C_{1-6}alkyl,

(3) C_{3-6}cycloalkyl,

(4) aryl, and

(5) heteroaryl;

R^i is selected from:

(1) hydrogen,

(2) C_{1-6}alkyl,

(3) C_{3-6}cycloalkyl,

(4) aryl, and

(5) heteroaryl;

R^j is selected from:

(1) hydrogen,

(2) C_{1-6}alkyl,

(3) C_{3-6}alkenyl,

(4) C_{3-6}alkynyl,

(5) C_{3-6}cycloalkyl,

(6) C_{2-5}cycloheteroalkyl,

(7) aryl, and

(8) heteroaryl;

R^k is selected from:

(1) hydrogen, and

(2) C_{1-6}alkyl;

R^L is selected from:

(1) hydrogen,

(2) C_{1-6}alkyl,

(3) C_{3-6}cycloalkyl,

(4) aryl, and

(5) heteroaryl;

m is independently selected from 0, 1 and 2;

n is independently selected from 2, 3, 4, 5 and 6;

p is independently selected from 0, 1, 2 and 3;

q is independently selected from 0, 1, 2 and 3;

r is independently selected from 0, 1 and 2;

s is independently selected from 0, 1, 2, 3, 4, 5, and 6; and

t is independently selected from 0, 1, 2, 3, 4, 5, and 6.

3. The compound according to Claim 1 wherein A is selected from the group consisting of:

(1) aryl, and

(2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

4. The compound according to Claim 1 wherein A is selected from the group consisting of:

(1) phenyl,

(2) pyridine, and

(3) thiazole,

wherein phenyl, pyridine and thiazole are unsubstituted or substituted with one to five substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 1 wherein A is selected from the group consisting of:

(1) phenyl, and

(2) pyridine,

whererin phenyl and pyridine are unsubstituted or substituted with one to four substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

6. The compound according to Claim 1 wherein B is independently selected from the group consisting of:

(1) -C_{3-12}cycloalkyl,

(2) -C_{2-11}cycloheteroalkyl,

(3) -C_{1-6}alkyl-C_{3-12}cycloalkyl,

(4) -C_{1-6}alkyl-C_{2-11}cycloheteroalkyl,

(5) -C_{1-6}alkyl-O-C_{3-12}cycloalkyl, and

(6) -C_{1-6}alkyl-O-C_{2-11}cycloheteroalkyl,

wherein alkyl, cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to six substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

7. The compound according to Claim 1 wherein B is independently selected from the group consisting of:

(1) cyclopropane,

(2) cyclobutane,

(3) cyclopentane,

(4) cyclohexane,

(5) bicyclo[3.2.1]octane,

(6) bicyclo[3.1.0]hexane,

(7) bicyclo[2.2.2]octane,

(8) spiro[2.5]octane,

(9) bicyclo[1.1.1]pentane,

(10) spiro[3.3]heptane,

(11) spiro[2.3]hexane, spiro[2.2]pentane,

(12) piperidine,

(13) tetrahydropyran, and

(14) chromane,

wherein B is unsubstituted or substituted with one to six substituents selected from R^b;

or a pharmaceutically acceptable salt thereof.

8. The compound according to Claim 1 wherein B is independently selected from the group consisting of:

(1) cyclopropane,

(2) cyclobutane,

(3) cyclopentane,

(4) cyclohexane,

(5) bicyclo[3.2.1]octane,

(6) bicyclo[3.1.0]hexane,

(7) bicyclo[2.2.2]octane,

(8) spiro[2.5]octane,

(9) bicyclo[1.1.1]pentane,

(10) spiro[3.3]heptane,

(11) spiro[2.3]hexane, spiro[2.2]pentane,

(12) piperidine, and

(13) tetrahydropyran,

wherein B is unsubstituted or substituted with one to six substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

9. The compound according to Claim 1 wherein B is independently selected from the group consisting of:

(1) -C_{3-12}cycloalkyl, and

(2) -C_{2-11}cycloheteroalkyl,

wherein cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to six substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

10. The compound according to Claim 1 wherein B is independently selected from the group consisting of:

(1) cyclobutane,

(2) cyclohexane, and

(3) tetrahydropyran,

wherein cyclobutane, cyclohexane and tetrahydropyran are unsubstituted or substituted with one to six substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

11. The compound according to Claim 1 wherein R^1 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl, and

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^c; or a pharmaceutically acceptable salt thereof.

12. The compound according to Claim 1 wherein R^2 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl, and

(4) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl, and

(4) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^4 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl, and

(4) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^5 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl, and

(4) -C_{3-6}cycloalkyl,

wherein alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^f;

or a pharmaceutically acceptable salt thereof.

13. The compound according to Claim 1 wherein R^2 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^4 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^5 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^6 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^g; and

R^7 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein alkyl, and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^g;

or a pharmaceutically acceptable salt thereof.

14. The compound according to Claim 1 wherein

R^8 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to five substituents selected from halogen; and

R^9 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to five substituents selected from halogen;

or a pharmaceutically acceptable salt thereof.

15. The compound according to Claim 1 wherein

A is selected from the group consisting of:

(1) aryl, and

(2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^a; and

B is independently selected from the group consisting of:

(1) -C_{3-12}cycloalkyl,

(2) -C_{2-11}cycloheteroalkyl,

(3) -C_{1-6}alkyl-C_{3-12}cycloalkyl,

(4) -C_{1-6}alkyl-C_{2-11}cycloheteroalkyl,

(5) -C_{1-6}alkyl-O-C_{3-12}cycloalkyl, and

(6) -C_{1-6}alkyl-O-C_{2-11}cycloheteroalkyl,

wherein alkyl, cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to six substituents selected from R^b;

or a pharmaceutically acceptable salt thereof.

16. The compound according to Claim 1 wherein

R^1 is hydrogen;

R^2, R^3, R^4 and R^5 are deuterium or hydrogen;

R^6 and R^7 are CH_3 or hydrogen; and

R^8 and R^9 are hydrogen;

or a pharmaceutically acceptable salt thereof.

17. The compound according to Claim 1 wherein

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8 and R^9 are hydrogen;

or a pharmaceutically acceptable salt thereof.

18. The compound according to Claim 1 wherein each R^a is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) -$S(O)_2C_{1-6}$alkyl,

(5) -C_{1-6}alkyl,

(6) -C_{2-6}alkenyl,

(7) -C_{3-6}cycloalkyl,

(8) -C_{2-6}cycloheteroalkyl,

(9) aryl,

(10) heteroaryl,

(11) -OH,

(12) -O-C_{1-6}alkyl,

(13) -O-C_{3-6}cycloalkyl, and

(14) -O-C_{2-6}cycloheteroalkyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

19. The compound according to Claim 1 wherein each R^a is independently selected from the group consisting of:

(1) halogen,

(2) -C_{1-6}alkyl, and

(3) -O-C_{1-6}alkyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

20. The compound according to Claim 1 wherein each R^a is independently selected from the group consisting of:

(1) halogen, and

(2) -C_{1-6}alkyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

21. The compound according to Claim 1 wherein each R^b is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) -$S(O)_2C_{1-6}$alkyl,

(5) -C_{1-6}alkyl,

(6) -C_{1-6}alkenyl,

(7) -C_{2-6}alkynyl,

(8) -C_{3-6}cycloalkyl,

(9) -C_{2-6}cycloheteroalkyl,

(10) aryl,

(11) heteroaryl,

(12) -OH,

(13) -O-C_{1-6}alkyl,

(14) -O-C_{3-6}cycloalkyl, and

(15) -O-C_{2-6}cycloheteroalkyl,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

22. The compound according to Claim 1 wherein each each R^b is independently selected from the group consisting of:

(1) halogen,

(2) -C_{1-6}alkyl,

(3) -C_{1-6}alkenyl,

(4) -C_{3-6}cycloalkyl, and

(5) -O-C_{1-6}alkyl,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;or a pharmaceutically acceptable salt thereof.

23. The compound according to Claim 1 wherein each each R^b is independently selected from the group consisting of:

(1) halogen, and

(2) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;

or a pharmaceutically acceptable salt thereof.

24. The compound according to Claim 1 wherein

A is selected from the group consisting of:

(1) phenyl,

(2) pyridine, and

(3) thiazole,

wherein phenyl, pyridine and thiazole are unsubstituted or substituted with one to five substituents selected from R^a;

B is independently selected from the group consisting of:

(1) cyclopropane,

(2) cyclobutane,

(3) cyclopentane,

(4) cyclohexane,

(5) bicyclo[3.2.1]octane,

(6) bicyclo[3.1.0]hexane,

(7) bicyclo[2.2.2]octane,

(8) spiro[2.5]octane,

(9) bicyclo[1.1.1]pentane,

(10) spiro[3.3]heptane,

(11) spiro[2.3]hexane, spiro[2.2]pentane

(12) piperidine,

(13) tetrahydropyran, and

(14) chromane,

wherein B is unsubstituted or substituted with one to six substituents selected from R^b;

R^1 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl, and

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^c;

R^2 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl, and

(4) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl, and

(4) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^4 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl, and

(4) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^5 is selected from the group consisting of:

(1) hydrogen,

(2) deuterium,

(3) -C_{1-6}alkyl, and

(4) -C_{3-6}cycloalkyl,

wherein alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^6 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from Rg;

R^7 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein alkyl, and cycloalkyl is unsubstituted or substituted with one to five substituents selected from Rg;

R^8 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to five substituents selected from halogen;

R^9 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to five substituents selected from halogen;

R^a is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) -$S(O)_2C_{1-6}$alkyl,

(5) -C_{1-6}alkyl,

(6) -C_{2-6}alkenyl,

(7) -C_{3-6}cycloalkyl,

(8) -C_{2-6}cycloheteroalkyl,

(9) aryl,

(10) heteroaryl,

(11) -OH,

(12) -O-C_{1-6}alkyl,

(13) -O-C_{3-6}cycloalkyl, and

(14) -O-C_{2-6}cycloheteroalkyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl; and

each R^b is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) -S(O)$_2$$C_{1-6}$alkyl,

(5) -C_{1-6}alkyl,

(6) -C_{1-6}alkenyl,

(7) -C_{2-6}alkynyl,

(8) -C_{3-6}cycloalkyl,

(9) -C_{2-6}cycloheteroalkyl,

(10) aryl,

(11) heteroaryl,

(12) -OH,

(13) -O-C_{1-6}alkyl,

(14) -O-C_{3-6}cycloalkyl, and

(15) -O-C_{2-6}cycloheteroalkyl,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;
or a pharmaceutically acceptable salt thereof.

25. The compound according to Claim 1 wherein

A is selected from the group consisting of:

(1) phenyl,

(2) pyridine, and

(3) thiazole,

wherein phenyl, pyridine and thiazole are unsubstituted or substituted with one to five substituents selected from R^a;

B is independently selected from the group consisting of:

(1) cyclopropane,

(2) cyclobutane,

(3) cyclopentane,

(4) cyclohexane,

(5) bicyclo[3.2.1]octane,

(6) bicyclo[3.1.0]hexane,

(7) bicyclo[2.2.2]octane,

(8) spiro[2.5]octane,

(9) bicyclo[1.1.1]pentane,

(10) spiro[3.3]heptane,

(11) spiro[2.3]hexane, spiro[2.2]pentane

(12) piperidine, and

(13) tetrahydropyran,

wherein B is unsubstituted or substituted with one to six substituents selected from R^b;

R^1 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl, and

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^c;

R^2 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^4 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^5 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^6 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein alkyl and cycloalkyl is unsubstituted or substituted with one to five substituents selected from R^g;

R^7 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, and

(3) -C_{3-6}cycloalkyl,

wherein alkyl, and cycloalkyl is unsubstituted or substituted with one to five substituents selected from Rg;

R^8 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to five substituents selected from halogen;

R^9 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein alkyl is unsubstituted or substituted with one to five substituents selected from halogen;

R^a is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) -$S(O)_2C_{1-6}$alkyl,

(5) -C_{1-6}alkyl,

(6) -C_{2-6}alkenyl,

(7) -C_{3-6}cycloalkyl,

(8) -C_{2-6}cycloheteroalkyl,

(9) aryl,

(10) heteroaryl,

(11) -OH,

(12) -O-C_{1-6}alkyl,

(13) -O-C_{3-6}cycloalkyl, and

(14) -O-C_{2-6}cycloheteroalkyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl; and

each R^b is independently selected from the group consisting of:

(1) CN,

(2) oxo,

(3) halogen,

(4) -$S(O)_2C_{1-6}$alkyl,

(5) -C_{1-6}alkyl,

(6) -C_{1-6}alkenyl,

(7) -C_{2-6}alkynyl,

(8) -C_{3-6}cycloalkyl,

(9) -C_{2-6}cycloheteroalkyl,

(10) aryl,

(11) heteroaryl,

(12) -OH,

(13) -O-C_{1-6}alkyl,

(14) -O-C_{3-6}cycloalkyl, and

(15) -O-C_{2-6}cycloheteroalkyl,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;
or a pharmaceutically acceptable salt thereof.

26. The compound according to Claim 1 wherein

A is selected from the group consisting of:

(1) phenyl, and

(2) pyridine,

whererin phenyl and pyridine are unsubstituted or substituted with one to four substituents selected from R^a;

B is independently selected from the group consisting of:

(1) -C_{3-12}cycloalkyl, and

(2) -C_{2-11}cycloheteroalkyl,

wherein cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to six substituents selected from R^b;

R^1 is hydrogen;

R^2, R^3, R^4 and R^5 are deuterium or hydrogen;

R^6 and R^7 are CH_3 or hydrogen;

R^8 and R^9 are hydrogen;

each R^a is independently selected from the group consisting of:

(1) halogen,

(2) -C_{1-6}alkyl, and

(3) -O-C_{1-6}alkyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl; and

each R^b is independently selected from the group consisting of:

(1) halogen,

(2) -C_{1-6}alkyl,

(3) -C_{1-6}alkenyl,

(4) -C_{3-6}cycloalkyl, and

(5) -O-C_{1-6}alkyl,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;

or a pharmaceutically acceptable salt thereof.

27. The compound according to Claim 1 wherein

A is selected from the group consisting of:

(1) phenyl, and

(2) pyridine,

whererin phenyl and pyridine are unsubstituted or substituted with one to four substituents selected from R^a;

B is independently selected from the group consisting of:

(1) -C_{3-12}cycloalkyl, and

(2) -C_{2-11}cycloheteroalkyl,

wherein cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to six substituents selected from R^b;

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8 and R^9 are hydrogen;

each R^a is independently selected from the group consisting of:

(1) halogen,

(2) -C_{1-6}alkyl, and

(3) -O-C_{1-6}alkyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl; and

each R^b is independently selected from the group consisting of:

(1) halogen,

(2) -C_{1-6}alkyl,

(3) -C_{1-6}alkenyl,

(4) -C_{3-6}cycloalkyl, and

(5) -O-C_{1-6}alkyl,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;
or a pharmaceutically acceptable salt thereof.

28. The compound according to Claim 1 selected from:

(1) N-((R)-3-chloro-4-fluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-3-oxopiperazine-1-carboxamide;

(2) N-((S)-3-chloro-4-fluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-3-oxopiperazine-1-carboxamide;

(3) N-((R)-(3-chloro-4-fluorophenyl)(8,8-difluorobicyclo[3.2.1]octan-3-yl)methyl)-3-oxopiperazine-1-carboxamide;

(4) N-((S)-(3-chloro-4-fluorophenyl)(8,8-difluorobicyclo[3.2.1]octan-3-yl)methyl)-3-oxopiperazine-1-carboxamide;

(5) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(8,8-difluorobicyclo[3.2.1]octan-3-yl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(6) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(8,8-difluorobicyclo[3.2.1]octan-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(7) N-((R)-(4-chlorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-3-oxopiperazine-1-carboxamide;

(8) N-((R)-(4-chlorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-3-oxopiperazine-1-carboxamide;

(9) N-((S)-(4-chlorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-3-oxopiperazine-1-carboxamide;

(10) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(trans-4-(trifluoromethyl)-cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(11) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(trans-4-(trifluoromethyl)-cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(12) (R)-2-methyl-3-oxo-N-((R)-(trans-4-(trifluoromethyl)cyclohexyl)(3,4,5-trifluorophenyl)methyl)piperazine-1-carboxamide;

(13) (R)-2-methyl-3-oxo-N-((S)-(trans-4-(trifluoromethyl)cyclohexyl)(3,4,5-trifluorophenyl)methyl)piperazine-1-carboxamide;

(14) (2R)-N-((R)-(3-chloro-4-fluorophenyl)((1R,3s,5S)-6,6-difluorobicyclo-[3.1.0]hexan-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(15) (2R)-N-((S)-(3-chloro-4-fluorophenyl)((1R,3s,5S)-6,6-difluorobicyclo-[3.1.0]hexan-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(16) (2R)-N-((R)-(3,4-difluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(17) (2R)-N-((S)-(3,4-difluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(18) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(19) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(20) N-((R)-(3-chloro-2,4-difluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)-methyl)-3-oxopiperazine-1-carboxamide;

(21) N-((S)-(3-chloro-2,4-difluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)-methyl)-3-oxopiperazine-1-carboxamide;

(22) (R)-N-((R)-(3-chloro-2,4-difluorophenyl)((1R,3s,5S)-6,6-difluorobicyclo-[3.1.0]hexan-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(23) (R)-N-((S)-(3-chloro-2,4-difluorophenyl)((1R,3s,5S)-6,6-difluorobicyclo-[3.1.0]hexan-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(24) N-((R)-(3-chloro-4-fluorophenyl)(4-(trifluoromethyl)bicyclo[2.2.2]octan-1-yl)methyl)-3-oxopiperazine-1-carboxamide;

(25) N-((S)-(3-chloro-4-fluorophenyl)(4-(trifluoromethyl)bicyclo[2.2.2]octan-1-yl)methyl)-3-oxopiperazine-1-carboxamide;

(26) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(4,4-difluorocyclohexyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(27) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(4,4-difluorocyclohexyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(28) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(4,4-difluorocyclohexyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(29) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(4,4-difluorocyclohexyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(30) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(31) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(32) (2R)-N-((R)-(4-chlorophenyl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(33) (2R)-N-((S)-(4-chlorophenyl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(34) N-((R)-(3-chloro-4-fluorophenyl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxamide;

(35) N-((S)-(3-chloro-4-fluorophenyl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxamide;

(36) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(1-(R)-(1,1,1-trifluoropropan-2-yl)-piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxamide;

(37) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(1-(S)-(1,1,1-trifluoropropan-2-yl)piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxamide;

(38) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(1-(R)-(1,1,1-trifluoropropan-2-yl)piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxamide;

(39) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(1-(S)-(1,1,1-trifluoropropan-2-yl)piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxamide;

(40) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(trans-1,1-difluorospiro[2.5]octan-6-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(41) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(trans-1,1-difluorospiro[2.5]octan-6-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(42) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(cis-1,1-difluorospiro[2.5]octan-6-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(43) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(cis-1,1-difluorospiro[2.5]octan-6-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(44) (R)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(45) (R)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(46) (R)-N-((S)-(3-chloro-2,4-difluorophenyl)(cis-3-(trifluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(47) (R)-N-((R)-(3-chloro-2,4-difluorophenyl)(cis-3-(trifluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(48) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-cyclopropylcyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(49) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(cis-3-cyclopropylcyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(50) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-cyclopropylcyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(51) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(cis-3-cyclopropylcyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(52) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-1,1-difluorospiro[2.3]hexan-5-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(53) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(cis-1,1-difluorospiro[2.3]hexan-5-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(54) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-1,1-difluorospiro[2.3]hexan-5-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(55) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(cis-1,1-difluorospiro[2.3]hexan-5-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(56) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(6,6-difluorospiro[3.3]heptan-2-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(57) 2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(6,6-difluorospiro[3.3]heptan-2-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(58) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(3,3-difluorocyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(59) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(3,3-difluorocyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(60) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(3-methylenecyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(61) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(3-methylenecyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(62) N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-3-oxopiperazine-1-carboxamide;

(63) (R)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-cyclopropyl-3-oxopiperazine-1-carboxamide;

(64) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-cyclopropyl-3-oxopiperazine-1-carboxamide;

(65) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(spiro[2.3]hexan-5-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(66) (2R)-N-((S)(3-chloro-2,4-difluorophenyl)(spiro[2.3]hexan-5-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(67) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-(difluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(68) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(difluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(69) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]-pentan-1yl)methyl)- 2-methyl-3-oxopiperazine-1-carboxamide;

(70) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(3-(trifluoromethyl)bicyclo-[1.1.1]pentan-1-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(71) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(3,3-dimethylcyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(72) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(3,3-dimethylcyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(73) N-((R)-(3-chloro-2,4-difluorophenyl)(3,3-dimethylcyclobutyl)methyl)-3-oxopiperazine-1-carboxamide;

(74) N-((S)-(3-chloro-2,4-difluorophenyl)(3,3-dimethylcyclobutyl)methyl)-3-oxopiperazine-1-carboxamide;

(75) (2R)-N-((R)-(3,3-dimethylcyclobutyl)(6-(trifluoromethyl)pyridin-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(76) (2R)-N-((S)-(3,3-dimethylcyclobutyl)(6-(trifluoromethyl)pyridin-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(77) N-((R)-(3-chloro-4-fluorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-3-oxopiperazine-1-carboxamide;

(78) N-((S)-(3-chloro-4-fluorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-3-oxopiperazine-1-carboxamide;

(79) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(80) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(81) (2R)-N-((R)-(4-fluoro-3-methylphenyl)(trans-4-(trifluoromethyl)cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(82) (2R)-N-((S)-(4-fluoro-3-methylphenyl)(trans-4-(trifluoromethyl)cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(83) (2R)-N-((R)-(4-fluoro-3-methylphenyl)(cis-4-(trifluoromethyl)cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(84) (2R)-N-((S)-(4-fluoro-3-methylphenyl)(cis-4-(trifluoromethyl)cyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(85) (2R)-N-((R)-(4-chloro-3-(difluoromethyl)phenyl)(cis-4-(trifluoromethyl) cyclohexyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(86) (2R)-N-((R)-(4-chloro-3-(difluoromethyl)phenyl)(trans-4-(trifluoromethyl) cyclohexyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(87) (2R)-N-((S)-(4-chloro-3-(difluoromethyl)phenyl)(cis-4-(trifluoromethyl) cyclohexyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(88) (2R)-N-((S)-(4-chloro-3-(difluoromethyl)phenyl)(trans-4-(trifluoromethyl) cyclohexyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(89) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(trans-3-(difluoromethoxy)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(90) (2R)-N-((R)-(3-chloro-4-fluorophenyl) (cis-3-(difluoromethoxy) cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(91) (2R)-N-((S)-(3-chloro-4-fluorophenyl) (cis-3-(difluoromethoxy) cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(92) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(trans-3-(difluoromethoxy)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(93) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-(difluoromethoxy)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(94) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(cis-3-(difluoromethoxy)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(95) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(cis-3-(difluoromethoxy)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(96) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(difluoromethoxy)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(97) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-methoxycyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(98) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)(cis-3-methoxycyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(99) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(cis-3-methoxycyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(100) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-methoxycyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(101) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)((R)-spiro[2.2]pentan-1-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(102) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)((S)-spiro[2.2]pentan-1-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(103) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)(R)-spiro[2.2]pentan-1-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(104) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)((S)-spiro[2.2]pentan-1-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(105) (2R)-N-((R)-(3-chloro-2,4-difluoro phenyl)((R)-3,3-difluorocyclopentyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(106) (2R)-N-((R)-(3-chloro-2,4-difluoro phenyl)((S)-3,3-difluorocyclopentyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(107) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)((R)-(3,3-difluorocyclopentyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(108) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)((S)-3,3-difluorocyclopentyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(109) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(110) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(cis-3-(trifluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(111) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(112) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(cis-3-(trifluoromethyl)cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(113) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(cis-3-(2,2,2-trifluoroethoxy)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(114) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(cis-3-(2,2,2-trifluoroethoxy)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(115) (2R)-N-((R)-(3-chloro-4-fluorophenyl)(trans-3-(2,2,2-trifluoroethoxy)-cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(116) (2R)-N-((S)-(3-chloro-4-fluorophenyl)(trans-3-(2,2,2-trifluoroethoxy)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(117) N-((R)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(trans-4-(trifluoromethyl)-cyclohexyl) methyl)-3-oxopiperazine-1-carboxamide;

(118) N-((S)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(trans-4-(trifluoromethyl)cyclo-hexyl)methyl)-3-oxopiperazine-1-carboxamide;

(119) (2R)-N-((R)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(4,4-difluorocyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(120) (2R)-N-((S)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(4,4-difluorocyclohexyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(121) (2R)-N-((R or S)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(cis-3-(trifluoromethyl)-cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(122) (2R)-N-((R or S)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(trans-3-(trifluoro-methyl)-cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(123) (2R)-N-((S or R)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(trans-3-(trifluoro-methyl)-cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(124) (2R)-N-((S or R)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(cis-3-(trifluoro-methyl)-cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(125) (2R)-N-((R or S)-1-(3-chloro-4-fluorophenyl)-1-(cis-3-(trifluoromethyl)-cyclobutyl)-ethyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(126) (2R)-N-((R or S)-1-(3-chloro-4-fluorophenyl)-1-(trans-3-(trifluoromethyl)-cyclobutyl)-ethyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(127) (2R)-N-((S or R)-1-(3-chloro-4-fluorophenyl)-1-(cis-3-(trifluoromethyl)-cyclobutyl)-ethyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(128) (2R)-N-((S or R)-1-(3-chloro-4-fluorophenyl)-1-(trans-3-(trifluoromethyl)-cyclobutyl)-ethyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(129) (2R)-N-((R)-(3-fluoro-4-(trifluoromethoxy)phenyl)(trans-3-(trifluoromethyl)-cyclo-butyl) methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(130) (2R)-N-((S)-(3-fluoro-4-(trifluoromethoxy)phenyl)(trans-3-(trifluoromethyl)-cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(131) ((2R)-N-((R)-(2-fluoro-4-(trifluoromethoxy)phenyl)(trans-3-(trifluoromethyl)-cyclobutyl)- methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(132) (2R)-N-((S)-(2-fluoro-4-(trifluoromethoxy)phenyl)(trans-3-(trifluoromethyl)-cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(133) (2R)-N-((R)-(4-fluoro-3-(trifluoromethyl)phenyl)(trans-3-(trifluoromethyl)cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(134) (2R)-N-((S)-(4-fluoro-3-(trifluoromethyl)phenyl)(trans-3-(trifluoromethyl)-cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(135) N-((R)-(4-fluoro-3-(trifluoromethyl)phenyl)(trans-3-(trifluoro methyl)-cyclobutyl)-methyl)-3-oxopiperazine-1-carboxamide;

(136) N-((S)-(4-fluoro-3-(trifluoromethyl)phenyl)(trans-3-(trifluoro methyl)cyclobutyl)-methyl)-3-oxopiperazine-1-carboxamide;

(137) (2R)-N-((R)-(3-chloro-2-fluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(138) (2R)-N-((S)-(3-chloro-2-fluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(139) (2R)-N-((R)-(3-chloro-4-(trifluoromethoxy)phenyl)(3-(trifluoromethyl) cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(140) (2R)-N-((S)-(3-chloro-4-(trifluoromethoxy)phenyl)(3-(trifluoromethyl) cyclobutyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(141) (2R)-2-methyl-3-oxo-N-((trans-4-(trifluoromethyl)cyclohexyl)((R)-2-(trifluoro-methyl)thiazol-4-yl)methyl)piperazine-1-carboxamide;

(142) (2R)-2-methyl-3-oxo-N-((trans-4-(trifluoromethyl) cyclohexyl)((S)-2-(trifluoro-methyl)thiazol-4-yl)methyl)piperazine-1-carboxamide;

(143) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)((3R, 6R)-6-(trifluoromethyl)-tetrahydro-2H-pyran-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(144) (2R)-N-((R)-(3-chloro-2,4-difluorophenyl)((3S, 6S)-6-(trifluoromethyl)-tetrahydro-2H-pyran-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(145) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)((3R, 6R)-6-(trifluoromethyl)-tetrahydro-2H-pyran-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(146) (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)((3S, 6S)-6-(trifluoromethyl)-tetrahydro-2H-pyran-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(147) (2R)-N-(R)-(3-chloro-2,4-difluorophenyl)(trans-2-(trifluoromethyl)cyclopropyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(148) (2R)-N-(R)-(3-chloro-2,4-difluorophenyl)(trans-2-(trifluoromethyl)cyclopropyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(149) (2R)-N-(S)-(3-chloro-2,4-difluorophenyl)(trans-2-(trifluoromethyl)cyclopropyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(150) (2R)-N-(S)-(3-chloro-2,4-difluorophenyl)(trans-2-(trifluoromethyl)cyclopropyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(151) (2R)-N-((R or S)-(3-chloro-2,4-difluorophenyl)(cis-3-(trifluoromethyl)-cyclopentyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(152) (2R)-N-((R or S)-(3-chloro-2,4-difluorophenyl)(cis-3-(trifluoromethyl)-cyclopentyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(153) (2R)-N-((R or S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)-cyclopentyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide; and

(154) (2R)-N-((R or S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclopentyl)-methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

or a pharmaceutically acceptable salt thereof.

29. The compound according to Claim 1 selected from:

(1) (R)-N-((S)-(3-chloro-2,4-difluorophenyl)((1r,3S)-3-(trifluoromethyl)cyclobutyl)methyl)-2-methyl-3-oxopiperazine-5,5,6,6-d4-1-carboxamide;

(2) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((1r,3S)-3-(trifluoromethyl)cyclobutyl)methyl)-2-methyl-3-oxopiperazine-5,5,6,6-d4-1-carboxamide;

(3) (2R)-N-((1(R or S))-(4-fluoro-3-(trifluoromethyl)phenyl)-*trans*-(6-(trifluoromethyl)-tetrahydro-2H-pyran-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(4) (2R)-N-((1(R or S))-(4-fluoro-3-(trifluoromethyl)phenyl)-*trans*-(6-(trifluoromethyl)-tetrahydro-2H-pyran-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(5) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((1r,3S)-3-(trifluoromethyl)cyclobutyl)methyl)-2-(fluoromethyl)-3-oxopiperazine-2-d-1-carboxamide;

(6) (R)-N-((R)-(3-chloro-2,4-difluorophenyl)((R)-chroman-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide; s

(7) (R)-N-((S)-(3-chloro-2,4-difluorophenyl)((R)-chroman-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;

(8) (R)-N-((R)-(3-chloro-2,4-difluorophenyl)((S)-chroman-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;
(9) (R)-N-((S)-(3-chloro-2,4-difluorophenyl)((S)-chroman-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide;
(10) (R)-N-((S)-(3-chloro-2,4-difluorophenyl)((1r,3S)-3-(trifluoromethyl)cyclobutyl)methyl)-3-oxo-2-(trifluoromethyl)piperazine-1-carboxamide;
(11) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((1r,3S)-3-(trifluoromethyl)cyclobutyl)methyl)-3-oxo-2-(trifluoromethyl)piperazine-1-carboxamide; and
(12) (R)-N-((S)-(3-chloro-2,4-difluorophenyl)((1r,3S)-3-(trifluoromethyl)cyclobutyl)methyl)-2-(hydroxymethyl)-3-oxopiperazine-1-carboxamide;
or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical composition comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

31. ~~The u~~Use of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, ~~for~~ in the preparation of a medicament ~~useful~~ for the treatment of a disorder, condition, or disease that is responsive to the inhibition of $Na_v1.8$ channel activity in a mammal in need thereof.

32. ~~The u~~Use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, ~~for~~ in the manufacture of a medicament for the treatment, prevention or control of a pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.

33. The use of Claim 32 wherein the disorder is a pain disorder.

34. The use of Claim 33 wherein the pain disorder is selected from: acute pain, inflammatory pain, or neuropathic pain.

35. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for use in therapy.

~~36. A method of treating or preventing a disorder, condition or disease that is responsive to the inhibition of $Na_v1.8$ channel activity in a patient in need thereof comprising~~

~~administration of a therapeutically effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.~~

~~37. The method of Claim 36 wherein the disorder is selected from: pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.~~

~~38. The method of Claim 37 wherein the disorder is a pain disorder.~~

~~39. The method of Claim 38 wherein the pain disorder is selected from: acute pain, inflammatory pain, or neuropathic pain.~~

36. The compound according to Claim 1 which is (R)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide; or a pharmaceutically acceptable salt thereof.

37. The compound according to Claim 1 which is (R)-N-((S)-(3-chloro-2,4-difluorophenyl)((trans)-3-(trifluoromethyl)cyclobutyl)methyl)-2-methyl-3-oxopiperazine-5,5,6,6-d4-1-carboxamide; or a pharmaceutically acceptable salt thereof.

38. The compound according to Claim 1 which is (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((trans)-3-(trifluoromethyl)cyclobutyl)methyl)-2-methyl-3-oxopiperazine-5,5,6,6-d4-1-carboxamide; or a pharmaceutically acceptable salt thereof.

39. The compound according to Claim 1 which is N-((R)-3-chloro-4-fluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-3-oxopiperazine-1-carboxamide; or a pharmaceutically acceptable salt thereof.

40. The compound according to Claim 1 which is N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)methyl)-3-oxopiperazine-1-carboxamide; or a pharmaceutically acceptable salt thereof.

41. The compound according to Claim 1 which is (2R)-N-((S)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(trans-3-(trifluoromethyl)cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide; or a pharmaceutically acceptable salt thereof.

42. The compound according to Claim 1 which is (2R)-N-((R)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(trans-3-(trifluoromethyl)cyclobutyl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide; or a pharmaceutically acceptable salt thereof.

43. The compound according to Claim 1 which is (2R)-N-((S)-(3-chloro-2,4-difluorophenyl)((3S, 6S)-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)methyl)-2-methyl-3-oxopiperazine-1-carboxamide; or a pharmaceutically acceptable salt thereof.